SEOUL, South Korea, April 21, 2025 /PRNewswire/ -- DAAN Biotherapeutics, a leading innovative drug development company specializing in T-Cell receptor (TCR)-based therapies, has signed an exclusive licensing agreement with GC Cell, a gene and cell therapy firm, for the tumor...
Hence then, the article about daan biotherapeutics and gc cell sign exclusive technology transfer agreement for tumor antigen specific antibody sequence to advance car t and car nk cell therapies was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( DAAN Biotherapeutics and GC Cell Sign Exclusive Technology Transfer Agreement for Tumor Antigen-Specific Antibody Sequence to Advance CAR-T and CAR-NK Cell Therapies )
Also on site :
- Primary school teacher banned after drinking can of beer in classroom and eating mints after every sip
- Greenland warns of ‘red lines’ in talks with US
- A New Lawsuit Is Taking Aim at Costco’s Beloved $4.99 Rotisserie Chicken